Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Osteoporosis and Sarcopenia
NCT06154707Phase 3Unknown
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in osteoporosis, Sarcopenia. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteoporosisSarcopenia
Beyond the preview
Go deeper on NCT06154707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154707.